Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

Basit Öğe Kaydı
dc.authoridgülmez, ahmet/0000-0002-3353-344X
dc.authoridBalçık, Onur Yazdan/0000-0002-3386-2075
dc.authoridKivrak Salim, Derya/0000-0003-4107-3460
dc.authoridPaksoy, Nail/0000-0003-4636-2595
dc.authoridŞenocak Taşçı, Elif/0000-0002-1686-1628
dc.authorwosidgülmez, ahmet/ABI-8218-2020
dc.authorwosidmustafa, Muhammed/HME-1300-2023
dc.authorwosidBalçık, Onur Yazdan/GXM-6652-2022
dc.authorwosidKarakurt, Melek/AAO-5495-2020
dc.authorwosidKivrak Salim, Derya/A-3920-2015
dc.authorwosidPaksoy, Nail/HKF-3015-2023
dc.authorwosidŞenocak Taşçı, Elif/KBD-3048-2024
dc.contributor.authorTasci, Elif Senocak
dc.contributor.authorOyan, Basak
dc.contributor.authorSonmez, Ozlem
dc.contributor.authorMutlu, Arda Ulas
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorOner, Irem
dc.contributor.authorCinkir, Havva Yesil
dc.date.accessioned2024-08-04T20:58:38Z
dc.date.available2024-08-04T20:58:38Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.descriptionASCO Gastrointestinal Cancers Symposium -- JAN 20-22, 2022 -- San Francisco, CAen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1200/JCO.2022.40.4_suppl.202
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue4en_US
dc.identifier.urihttps://doi.org/10.1200/JCO.2022.40.4_suppl.202
dc.identifier.urihttps://hdl.handle.net/11616/103026
dc.identifier.volume40en_US
dc.identifier.wosWOS:000770995900198en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleEfficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group studyen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu